Effects of a new calcium channel blocker, TA 3090, on serum lipoprotein levels in mild to moderate essential hypertension.

Abstract

The 25 hypertensive patients received 20 to 40 mg of TA 3090 daily for 12 weeks. Blood pressures declined significantly during treatment, from a mean of 162/98 to 145/88 mmHg. There were no significant changes in levels of total or very low-density lipoprotein cholesterol or triglyceride, in levels of low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, HDL2 cholesterol, HDL3 cholesterol, or in levels of apolipoprotein (apo) B, C-II, C-III, or E. Apo A-I and A-II levels increased significantly from 130 and 29.2 mg/dl before treatment to 152 and 31.4 mg/dl at 12 weeks. Mean serum creatinine levels decreased significantly from 0.92 to 0.80 mg/dl. No other drug-related changes in laboratory test results or side effects were noted. It is concluded that TA 3090 is a safe and effective treatment for mild to moderate hypertension.

• Authors: J Sasaki, M Ideishi, K Saku, K Arakawa, K Tominaga, Y Saeki, N Otake, K Kawasaki, K Shirai, I Sumida
• Journal: Clinical therapeutics (Clin Ther) 1990 Jul-Aug Vol. 12 Issue 4 Pg. 327-34 ISSN: 0149-2918 [Print] United States
• PMID: 2224947 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Calcium Channel Blockers
• Lipoproteins
• Thiazepines
• clentiazem
• Diltiazem

Topics

• Adult
• Aged
• Calcium Channel Blockers (adverse effects, therapeutic use)
• Diltiazem (analogs & derivatives)
• Female
• Humans
• Hypertension (drug therapy)
• Lipoproteins (blood)
• Male
• Middle Aged
• Severity of Illness Index
• Thiazepines (adverse effects, therapeutic use)